Free tool
FAERS Monitor: Kalbitor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125277 or its brand name (Kalbitor, Ecallantide). Reports on generic versions are filed under their own applications.
Reports
1,869
Serious
1,138
61% of reports
Hospitalization
780
Death reported
34
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hereditary angioedema782
- off label use170
- drug ineffective147
- malaise86
- headache84
- product dose omission issue72
- pain70
- hypersensitivity68
- weight decreased68
- nausea67
- anaphylactic reaction62
- weight increased60
- therapeutic response decreased54
- vomiting53
- pneumonia52
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 9 |
| 2011 | 20 |
| 2012 | 67 |
| 2013 | 70 |
| 2014 | 197 |
| 2015 | 333 |
| 2016 | 499 |
| 2017 | 69 |
| 2018 | 124 |
| 2019 | 86 |
| 2020 | 84 |
| 2021 | 78 |
| 2022 | 62 |
| 2023 | 38 |
| 2024 | 38 |
| 2025 | 64 |
| 2026 | 31 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,290 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hereditary angioedemaSignal | 782 | 884.4 | 835.4 | 639,295 |
| anaphylactic reactionSignal | 62 | 12.6 | 9.9 | 654 |
| therapeutic response decreasedSignal | 54 | 10.0 | 7.7 | 431 |
| hypersensitivitySignal | 68 | 4.1 | 3.3 | 159 |
| weight increasedSignal | 60 | 3.0 | 2.4 | 80 |
| product dose omission issueSignal | 72 | 2.8 | 2.2 | 80 |
| weight decreasedSignal | 68 | 2.7 | 2.2 | 74 |
| malaiseSignal | 86 | 2.2 | 1.8 | 57 |
| off label useSignal | 170 | 2.2 | 1.9 | 113 |
| pneumonia | 52 | 1.8 | 1.4 | 18 |
| headache | 84 | 1.5 | 1.2 | 14 |
| pain | 70 | 1.3 | 1.0 | 4 |
| vomiting | 53 | 1.3 | 1.0 | 3 |
| drug ineffective | 147 | 1.3 | 1.1 | 8 |
| nausea | 67 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.